← Calendar
Readoutin 76d
Acerta Pharma BV — acalabrutinib
Phase 3 primary completion: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).
- Date
- Feb 2027
- Type
- Readout
- Indication
- Diffuse Large B-Cell Lymphoma
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Acerta Pharma BV
Apr2027
Readoutin 135d
Acerta Pharma BV — acalabrutinibPhase 3 primary completion: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).